uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from a technical perspective.
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
What made uniQure stock nearly double on Wednesday?
uniQure (QURE) stock is ripping higher this morning after the biopharmaceutical firm announced a major regulatory breakthrough with the FDA for its Huntington's disease gene therapy AMT-130. As investors cheered the disclosure, QURE pushed past its key moving averages (MAs) – and its relative strength index (RSI) climbed into the mid-80s, indicating intense buying pressure.
UniQure gets FDA green light to file for Huntington's gene therapy approval
Dutch drugmaker UniQure said on Wednesday the U.S. Food and Drug Administration has agreed that data from a mid-stage study could support an accelerated approval filing for its gene therapy to treat Huntington's disease.
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
uniQure (QURE) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.82 per share a year ago.
This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
QURE Stock Crashes 32% in a Week: Here's What You Should Know
uniQure stock plunges 32% in a week after the FDA says AMT-130 phase I/II Huntington's disease data are not sufficient as primary evidence for a potential marketing application.
